CELH
Celsius Holdings, Inc.
CELH has the edge over NOMD overall, supported by stronger fundamentals and stronger valuation.
NOMD
Nomad Foods Limited
NOMD has lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NOMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weak |
NOMD's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over NOMD in the historical PE scenario, which offers more potential upside but is not a forecast.
NOMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $10.64 | -8.7% |
| Current | 12x | $11.65 | — |
| Fair | 14x | $13.76 | +18% |
| Expensive | 20x | $20.09 | +72% |
Historical ranges are pointers, not guarantees.
NOMD's PE is 12x, but its earnings don't support one, so it isn't a reliable read right now.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over NOMD on the outlook, with more favorable earnings and revenue expectations.
NOMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Stable | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect NOMD's profitability to weaken, with its earnings and revenue holding steady.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
NOMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.98 | -34% |
| Q1 2026 | $1.00 | -35% |
| Q4 2025 | $1.01 | -34% |
| Q3 2025 | $1.43 | +5.1% |
| Q2 2025 | $1.48 | +5.7% |
| Q1 2025 | $1.54 | +25% |
| Q4 2024 | $1.54 | +22% |
| Q3 2024 | $1.36 | +3% |
NOMD has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over NOMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over NOMD on profitability, with a higher operating margin.
NOMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $804M | -3.1% |
| Q1 2026 | $794.5M | -5.9% |
| Q4 2025 | $858.8M | -2.6% |
| Q3 2025 | $835.8M | -2.2% |
| Q2 2025 | $829.7M | -0.8% |
| Q1 2025 | $844.4M | -3% |
| Q4 2024 | $881.4M | +4.3% |
| Q3 2024 | $854.9M | +0.8% |
NOMD's revenue grew through 2022 and has held roughly level since: $804M last quarter, down 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 12% | +0.5 points |
| Q1 2026 | 7.9% | -1.8 points |
| Q4 2025 | 9.1% | -2.4 points |
| Q3 2025 | 12% | -3.5 points |
| Q2 2025 | 12% | -1.7 points |
| Q1 2025 | 9.7% | +0.5 points |
| Q4 2024 | 12% | +2.8 points |
| Q3 2024 | 16% | +3 points |
NOMD's operating margin was 12% last quarter, up 0.5 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH has the edge over NOMD on cash flow, with more consistent year-over-year improvement.
NOMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $31.7M | -44% |
| Q1 2026 | $7.9M | -78% |
| Q4 2025 | $152.9M | -32% |
| Q3 2025 | $35M | -61% |
| Q2 2025 | $56.9M | +$66.7M |
| Q1 2025 | $35.4M | -60% |
| Q4 2024 | $224.5M | +27% |
| Q3 2024 | $90.6M | +0.7% |
NOMD still generates free cash flow, though less than at its 2024 peak: $227M over the past year.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
NOMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -1.9M shares |
| 1 year | -8.2% | -12.5M shares |
| 3 years | -19% | -33.6M shares |
| 5 years | -21% | -37.7M shares |
| Available history | -29% | -56.3M shares |
NOMD has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $137,232 |
| Q1 2026 | $26.8M |
| Q4 2025 | $49.1M |
| Q3 2025 | $56.7M |
| Q2 2025 | $64.7M |
| Q1 2025 | $54.3M |
| Q4 2024 | $84.2M |
| Q3 2024 | $27M |
NOMD spent $133M buying back its own shares over the past year, down 42% from the year before.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over NOMD on leverage, with a lower net debt burden relative to earnings.
NOMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 4.7x | High |
| Q1 2026 | 4.5x | High |
| Q3 2025 | 4.0x | High |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 3.6x | Elevated |
| Q3 2024 | 3.7x | Elevated |
| Q2 2024 | 3.8x | Elevated |
| Q1 2024 | 3.8x | Elevated |
NOMD's net debt is about 4.7 years of its operating earnings (EBITDA), up from 3.6 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
NOMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.0 | Neutral |
| Stochastic | 64.5 | Neutral |
NOMD's weekly RSI is 54 (neutral) and its Stochastic is 64 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
NOMD PE vs Consumer Defensive Sector
| Metric | NOMD | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 19x | 39% below |
| PE % | 30 | 18 | 12 pts above |
NOMD has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
NOMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.4 | 1.8% above |
| 20 week MA | $11.5 | 1.1% above |
| 50 week MA | $11.2 | 4.2% above |
| 100 week MA | $13.8 | 16% below |
| 200 week MA | $15.7 | 26% below |
NOMD has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
NOMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.0 | $25.2 | +15% |
| 2021 | $25.2 | $25.1 | -0.2% |
| 2022 | $25.1 | $17.1 | -32% |
| 2023 | $17.1 | $17.0 | -0.9% |
| 2024 | $17.0 | $16.6 | -2.3% |
| 2025 | $16.6 | $12.5 | -25% |
| 2026 YTD | $12.5 | $11.7 | -6.4% |
NOMD has the edge over CELH on returns for 2026, with the stronger performance.